Castle Biosciences, Inc.CSTLNASDAQ
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank55
5Y CAGR-26.0%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
-26.0%/yr
Long-term compound
Percentile
P55
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 19.00% |
| Q3 2025 | 8.69% |
| Q2 2025 | 444.95% |
| Q1 2025 | -124.77% |
| Q4 2024 | 4.40% |
| Q3 2024 | -2.75% |
| Q2 2024 | 451.10% |
| Q1 2024 | -136.77% |
| Q4 2023 | 270.85% |
| Q3 2023 | 232.38% |
| Q2 2023 | 85.12% |
| Q1 2023 | -323.98% |
| Q4 2022 | -14.85% |
| Q3 2022 | 41.96% |
| Q2 2022 | 58.00% |
| Q1 2022 | -670.59% |
| Q4 2021 | 54.66% |
| Q3 2021 | 4.74% |
| Q2 2021 | -77.31% |
| Q1 2021 | -744.42% |
| Q4 2020 | 85.45% |
| Q3 2020 | -121.89% |
| Q2 2020 | 5478.88% |
| Q1 2020 | -105.59% |
| Q4 2019 | 497.87% |
| Q3 2019 | 56.01% |
| Q2 2019 | -62.61% |
| Q1 2019 | 140.14% |
| Q4 2018 | -70.87% |
| Q3 2018 | 60.00% |
| Q2 2018 | -87.22% |
| Q1 2018 | 0.00% |